2.35

3.29% -0.0799

After Hours: 2.35

Barinthus Biotherapeutics Plc. ADR (BRNS)

Overview News Price History Financials Discussions Forecast

Barinthus Biotherapeutics Plc. ADR stock is currently priced at $2.35, with a 24-hour trading volume of 375. It has seen a -3.29% decreased in the last 24 hours and a -9.62% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.38 pivot point. If it approaches the $2.32 support level, significant changes may occur.

Previous Close:

$2.4299

Open:

$2.35

24h Volume:

375

Market Cap:

$91.73M

Revenue:

$13.42M

Net Income/Loss:

$-73.35M

P/E Ratio:

EPS:

Net Cash Flow:

$-56.34M

1W Performance:

+0.64%

1M Performance:

-9.62%

6M Performance:

-14.55%

1Y Performance:

+0.00%

1D Range:

$2.35

52W Range:

$1.82

$4.3898

Barinthus Biotherapeutics Plc. ADR Stock (BRNS) Company Profile

Name

Barinthus Biotherapeutics Plc. ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

44 1865 818 808

Address

Zeus Building, Unit 6-10 The Harwell Science & Innovation Campus Rutherford Avenue, Harwell

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

BRNS's Discussions on Twitter

Barinthus Biotherapeutics Plc. ADR Stock (BRNS) Latest News

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - Investing.com India

Investing.com India

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Benzinga

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

GlobeNewswire Inc.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

GlobeNewswire Inc.

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

Barinthus Biotherapeutics Plc. ADR Stock (BRNS) Financials Data

Barinthus Biotherapeutics Plc. ADR (BRNS) Revenue 2024

BRNS reported a revenue (TTM) of $13.42 million for the quarter ending June 30, 2023, a -58.18% decline year-over-year.

Barinthus Biotherapeutics Plc. ADR (BRNS) Net Income 2024

BRNS net income (TTM) was -$73.35 million for the quarter ending December 31, 2023, a -1,473% decrease year-over-year.

Barinthus Biotherapeutics Plc. ADR (BRNS) Cash Flow 2024

BRNS recorded a free cash flow (TTM) of -$56.34 million for the quarter ending December 31, 2023, a -173.90% decrease year-over-year.

Barinthus Biotherapeutics Plc. ADR (BRNS) Earnings per Share 2024

BRNS earnings per share (TTM) was -$1.92 for the quarter ending December 31, 2023, a -1,600% decline year-over-year.

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.